Open Access Article
This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence

A direct fixation of CO2 for isotopic labelling of hydantoins using iodine–phosphine charge transfer complexes

John-Paul J. Bow a, Valentina Adami b, Agostino Marasco b, Gaute Grønnevik a, Dean A. Rivers c, Guiseppe Alvaro c and Patrick J. Riss *ade
aSection for Organic Chemistry Department of Chemistry, University of Oslo Sem Sælands vei 26, 0371 Oslo, Norway. E-mail: Patrick.riss@kjemi.uio.no
bAutifony S.r.l., c/o Istituto di Ricerca Pediatrica Città della Speranza Corso Stati Uniti 4f, 35127 Padova, Italy
cAutifony Therapeutics Limited, c/o Stevenage Bioscience Catalyst Incubator, Gunnel Wood Road, Stevenage, Herts, SG1 2FX, UK
dDepartment of Clinical Neuroscience, Oslo University Hospitals HF Postboks 4950 Nydalen, 0424 Oslo, Norway
eDepartment of Chemistry, Johannes Gutenberg-University, Fritz Strassmann Weg 2, 55128 Mainz, Germany

Received 27th March 2022 , Accepted 30th May 2022

First published on 3rd June 2022


Abstract

Herein, we report a method for the isotopic labelling of hydantoins directly from CO2 by means of trimethyl-λ5-phosphine diiodide mediated carbonyl insertion. The method is suitable for 13C-labelling of diverse substrates and was implementated for 11C-labelling in PET-imaging facilities for the synthesis of radiotracers. Isolated yields of 90% and radiochemical yields of 89% were achieved for hydantoin containing drug candidates in formulation within 30 min with high molar activity (>400 MBq nmol−1).


Carbon dioxide is an attractive C1 building block with a wide scope of applications for isotopic labelling of drug molecules for pharmacological studies.1 The advent of imaging mass spectrometry has created a new need for 13C-labelled drug molecules, e.g. for the determination of receptor occupancy and identification of metabolites in target tissues.2 While imaging MS has high resolution, the destructive nature of MS requires tissue samples to be taken post mortem, which is not always an option in drug development. Instead, non-invasive positron emission tomography imaging (PET) with carbon-11 (11C) labelled isotopologues provide an optimal companion for high resolution imaging MS suitable for living subjects. Since carbon is practically ubiquitous in pharmaceuticals and biomolecules, isotopic substitution of a natC atom for a 11/13C-label offers an elegant solution to obtain complementary labelled compounds with identical properties for both methods. Direct fixation of 13CO2 has been demonstrated before, albeit with long reaction times incompatible with our goal for use with both 11C and 13C.3 Due to the short half-life of 11C (20.4 minutes), radiolabelling, purification, and quality control (QC) of 11C-radiotracers must be implemented within minute time-frames in close proximity to the PET site.1 In this light, it is advantageous to utilise the primary cyclotron product [11C]CO2 obtained from proton bombardment of 14N in presence of O2 for labelling rather than secondary labelling agents.4–11 Remaining challenges of [11C]CO2 are the low reactivity and solubility in organic solvents as well as the limited options for process design in typical PET centres.6

To study assets from Autifony's development pipeline we encountered a need for a direct and rapid method to isotopically label hydantoin-based drug candidates using the available synthetic precursor. We sought a carbonyl insertion method with CO2 at low partial pressure to bring the reactivity of phosgene to typical PET production sites involved in multicentre trials. In contrast to most literature methods this calls for trace 11CO2 in an He atmosphere. Metal catalysts were not an option as the need for metal determination by ICP-MS prior to release to satisfy cGMP guidelines had to be avoided. One particularly effective strategy to fixate CO2 between N-atoms is the use of phosphinimines11 to activate anilines to undergo a pericyclic reaction with [11C]CO2 to form aryl isocyanates.9,11,14 Isocyanates readily react with vicinal N-atoms to form hydantoins without the need for strong bases (Scheme 1), which was deemed advantageous to preserve chirality.


image file: d2cc01754g-s1.tif
Scheme 1 Recent methods for the incorporation of CO2.

The synthesis of 11C-labelled asymmetric ureas from N-aryl-triphenylphosphinimines and [11C]CO2 is a powerful method albeit limited by lack of shelf-stable or commercially available phosphinimines.11 Due to a general susceptibility to hydrolysis only a few N-aryl-triphenylphosphinimines have been described. N-Alkyl phosphinimines are virtually absent from literature for lack of the stabilizing resonance effects of the aromatic siblings.9b,12–15 By use of the Staudinger degradation phosphinimines are obtained in situ from electron-withdrawing azide groups in the substrate to direct the phosphinimine formation.11,14 However, in our case amine-to-azide conversion had to be dismissed for risk of racemisation and need of new synthetic intermediates. With both, isolation and degradation, out of question, we resorted to generation of labile phosphinimines in situ from primary aliphatic amines in the new approach described here. This allowed for using available intermediates without the need for any new GMP synthesis. Key to this novel method is an iodine-trimethyl-λ5-phosphine charge-transfer complex for direct access to aliphatic phosphinimines. As only aromatic examples have been used ever since the discovery of the phosphinimine, this work is the first instance of use of their aliphatic siblings in synthesis.13,16

Firstly, we devised a method to prepare the complex fresh from iodine and phosphines. Which proved to be most effective, reliable, and straightforward, providing access to previously undescribed P-I complexes in solid form. An excess of phosphine was found to suppress the formation of iodophosphonium triiodide, which forms in presence of excess I2. With phosphine in excess, two signals are observed via31P{1H} NMR spectroscopy indicating the presence of two isomers. These isomers are consistent with the literature most likely representing the axial trigonal-bipyramidal complex and a linear arrangement containing an I–I bond.17 The phosphine diiodide charge-transfer complexes generated in situ were found to effectively promote carbonyl insertion in feasibility studies in radiochemistry. Automation of all process steps including HPLC and formulation on Synthra radiosynthesis modules allowed for employing 11CO2 to rapidly screen the effect of individual reagents. In initial base screening experiments, triethylamine (NEt3) gave the highest radioactivity yield, stronger bases were omitted to avoid inversion of the 2-aminobutyramide.

Investigating the role of the phosphine revealed that sterically hindered phosphines were not particularly suitable, presumably due to a combination of stability and reactivity. Steric demand of phosphines is expressed in Tolman cone angles (θ).18 PPh3 (θ = 145) had the widest angle that still gave yield, albeit only traces. The larger P(NMe2)3 (θ = 157) and PCy3 (θ = 170) did not yield product.19 As the cone angle decreases, we start to see higher yields as shown with PMe2Ph, (θ = 122) giving a RCY of only 2.0% (Table 1, entry 4). Using alkyl phosphines with decreasing size maximized the yield as seen with PPr3, PBu3, and PMe3, with 12.4%, 21.4%, and the highest 33.4% yields, respectively (Table 1, entries 1–3). We surmised that the larger steric hindrance of these phosphines in relation to PMe3 (θ = 118) complicates a concerted step forming the 1,3,2-oxazaphosphetidin-4-one intermediate with CO2, thus allowing for evasion of the CO2 from the reaction mixture. The sterics of phosphine play a key role in the reactivity between the phosphine-diiodide electrophile and the amine.

Table 1 Effect of various phosphines on cyclisation of 18 with [11C]CO2a

image file: d2cc01754g-u1.tif

Entry Phosphine RCY Tolman cone angle (θ)18
5 min, NEt3, DMF/MeCN, RCY – isolated yield after HPLC.a Precursor dissolved in MeCN and NEt3 was added to a reaction vessel. The PR3I2 reagent was added to the reaction vessel containing the starting material and the mixture was sparged with He (3 min at 25 mL min−1). [11C]CO2 was added over 30 s at 15 mL min−1. After heating to 50 °C for 5 min, the mixture was diluted with 0.1% aqueous TFA (1:1, v/v) and injected into an HPLC system. Compounds were isolated by SPE extraction on an Oasis HLB cartridge and elution in 9% EtOH in water for injection.
1 PMe3 33.4% ± 6.6 (n = 3) 118
2 PBu3 21.4% ± 12.3 (n = 3) 132
3 PPr3 12.4% ± 0.4 (n = 2) 132
4 PMe2Ph 2.0% ± 0.7 (n = 2) 122
5 PCy3 0% 170
6 PPh3 Trace 145
7 P(NMe2)3 0% 157
8 P(OMe)3 0% 107
9 P(OPh)3 0% 128


Presumably due to the hindrance of a nucleophilic attack by RNH2 so that formation of the phosphinimine (Scheme 1) becomes less likely with increasing steric demand of the phosphine. We found this to be less of an issue in presence of 13CO2 at equal stoichiometry or when employing excess natural carbon dioxide at a partial pressure of 1 bar. However, slow rates of reaction may impede no-carrier added [11C]CO2 chemistry opening for alternative reaction pathways instead of CO2 fixation. [11C]CO2 is present at low partial pressure and will evade from the reaction mixture if not fixated rapidly. For efficient retention in the reaction mixture the radionuclide must be trapped at low temperature. These factors create a peculiar reaction condition wherein traces of n.c.a. [11C]CO2 are to be engaged. Starting materials are employed in a stoichiometric excess of e.g. 104[thin space (1/6-em)]:[thin space (1/6-em)]1 relative to [11C]CO2. Consequentially, reactions rates become independent of starting material consumption and depend only on the chemical activity (concentration) of trace CO2. As the CO2 must be trapped in a rapid reaction before it evades, the observation that low θ corresponds to high fixation of [11C]CO2 in the product can be connected to faster reaction rates. Presumably this is owed to much lower steric hindrance of the concerted, pericyclic reaction between the P[double bond, length as m-dash]N and O[double bond, length as m-dash]C molecular orbitals. It can be seen that the less stable aliphatic phosphines react sufficiently fast, which most likely due to lability of the intermediates. In contrast, PPh3 slowly forms a much more stable imine, resulting in a combination that does not react fast enough with n.c.a. [11C]CO2. PMe3Br2 and PMe3ICl were also made and tested, but produced no yield. On investigation of the incubation time before the addition of [11C]CO2 to the mixture, we found that immediate addition produced less than 1% isolated RCY, 17% RCY were obtained after 10 min. The optimal activation time was 5 min before delivery of [11C]CO2 providing an average RCY of 20% without fully optimized conditions. This incubation time allowed for purging the mixture with He to remove natCO2 prior to radionuclide delivery to improve molar activity. MeCN was the solvent of choice, providing slightly higher RCY than the DMF–MeCN mixture used for initial screenings.SI

The reagent stoichiometry was investigated with [11C]CO2 under optimized conditions. Firstly, with 0.5 equivalents (Table 2, entry 1i) was low yielding. Increasing the equivalents, we were able to achieve moderate yields of 48% with both 1.0 and 1.2 equivalents (Table 2, entries 2i and 3i). Further increasing the equivalents resulted in lower yields (Table 2, entries 4i and 5i). This plateau of yield is thought to be caused by the sub-stoichiometric amounts of [11C]CO2 available and the lifetime of the phosphinimine.

Table 2 Stoichiometric effects of PMe3I2 on both [11C]CO2 and CO2a

image file: d2cc01754g-u2.tif

Entry I 2 equiv. iRCYb iiNMR yield
RCY; isolated radiochemical yield.a Precursor dissolved in MeCN and NEt3 was added to a reaction vessel. The PR3I2 reagent was then added to the reaction vessel containing the starting material and the mixture was sparged with He (3 min at 25 mL min−1). [11C]CO2 was added over 30 s at 15 mL min−1. After heating to 50 °C for 5 min, the mixture was diluted with 0.1% aqueous TFA (1[thin space (1/6-em)]:[thin space (1/6-em)]1, v/v) and injected into a built-in HPLC system. Compounds were isolated by SPE extraction on an Oasis HLB cartridge and elution in 9% EtOH in water for injection.b 11CO2 is trapped in the reaction vessel at low temperature (>95% trapping at −40 °C), unreacted material outgases rapidly with heating. Increasing the chemical activity of 11CO2 in the reaction by a more reactive precursor that requires lower temperature is key to high RCY.
1 0.5 20.6% ± 0.1 (n = 2)
2 1.0 48.7% ± 7.1 (n = 2)
3 1.2 48.3% ± 4.1 (n = 3) 37% ± 22 (n = 3)
4 1.5 27.2% ± 2.8 (n = 2)
5 2.1 36.1% ± 0.3 (n = 2) 45% ± 8 (n = 3)
6 3.5 83% ± 20 (n = 3)
7 4 92% ± 10 (n = 6)
8 4.5 90% ± 17 (n = 3)


To test if the reaction is limited by the concentration of [11C]CO2 we investigated the reaction in the presence of excess natCO2 in an air-tight vessel to prevent evasion. Starting with 1.2 eq. (Table 2, entries 3ii) we obtained slightly lower yields than the experiments with 11C. Increasing the equivalents to 2.1 (Table 2, entry 5ii) resulted in improved yield. Further increasing the equivalents to 3.5 provided a yield of 83% (Table 2, entry 6ii). At 4 and 4.5 equivalents we obtained the maximum yields around 90% (Table 2, entries 7ii and 8ii). Careful monitoring of these studies by NMR revealed that the stoichiometric excess of PMe3I2 required to obtain high yields was due to the hydrolysis of the phosphinimine. We saw near complete conversion of PMe3 to PMe3 oxide in the presence of moisture while starting material was not consumed completely. This implied that the amine consumed several equivalents of PMe3I2 to cycle through phosphinimine only to be hydrolysed back to amine and PMe3O, slowly depleting the reagent. At stoichiometric conditions in presence of excess H2O, the competing hydrolysis of the phosphinimine intermediate is faster than CO2 capture. The reaction is halted once the charge transfer complex is consumed, resulting in poor yields. Therefore, it is essential that precautions are taken to avoid excess moisture. This was achieved by adding molecular sieves to NMR solvents, using oven-dried glassware, and working with an excess of PMe3I2 complex to mitigate the effect of hydrolysis.

As we noted the broad synthetic applicability of the new method under stoichiometric conditions we decided to use it for carbon-13 labelling. A variety of model substrates (Fig. 1) were tested to further investigate both NMR conversion and isolated yields of carbon-13 labelled products.


image file: d2cc01754g-f1.tif
Fig. 1 Results for the direct incorporation of *CO2; (a) NMR yield from natCO2 and (b) isolated yield of the carbon-13-labelled compound.

Under optimized conditions substrate 1 gave quantitative NMR conversion to 1a and an isolated yield of the isotopically labelled analogue 1b of 76%. Compound 2 was made in 48% conversion isolated in 26%, owed to the hygroscopic starting material. Compound 3 gave a conversion of 81% but proved difficult to isolate in high yields obtaining only 66%. There was no conversion with substrates 4, 5, and 6. This is thought to be due to the formation of a six membered ring. For example, instead of 4 the starting material would allow for cyclisation of a 2,2,2-trimethyl-2,3-dihydro-2λ5-pyrido[2,3-d][1,3,2]diazaphosphinin-4(1H)-one. Substrate 7 provided the excellent conversion of 93% and was isolated in 77%. The hydantoins 8 and 9 were isolated in moderate yields of 48% and 74%, respectively. Hydantoin 10 was formed and isolated in over 60% yield while 11 showed 51% yield by NMR but was isolated in 8%. Substrate 12 was isolated in 81% while 13 provided both a moderate conversion and isolated yield. Compounds 14 and 15 gave very high conversions and were isolated in 90% and 76%. 16 was isolated in a yield of 70% from an NMR conversion of 73%. 17 provided 73% by NMR and 63% were isolated. With the substrate scope established, the method showed a convincing performance for labelling of the target hydantoins. The carbon-13 labelled Autifony assets 18–20 were isolated in 77% (18), 51% (19), and 81% (20) (Fig. 2).


image file: d2cc01754g-f2.tif
Fig. 2 Isotopic labelling and radiolabelling of drug candidates using [11C]CO2 (a) NMR yield (b) isolated yield with 13C.

Radiolabelling of the chiral KV3 modulators 18–20 in moderate to excellent yield with [11C]CO2 with retention of the stereocenter.SI In the case of [11C]18, a radiochemical yield of 49% and a molar activity (AM) of 218 MBq nmol−1 was obtained. [11C]19 and [11C]20 were obtained in an RCY of 35% and 89% and in a AM of 194–417 MBq nmol−1 at the time of injection into subjects. A Synthra synthesis module allowed for complete automation of the process. Purified and formulated [11C]18–20 were delivered to the PET scanner within 35 minutes from the end nuclide production and released for use within 2 half-lives.

In conclusion, we report a rapid method for direct synthesis of hydantoins from CO2 which was found suitable for labelling with carbon-13 in high yields. The preliminary usefulness of this method for translation into carbon-11 labelling of a series of KV3 modulators was equally successful. Through the new method we were able to utilize existing GMP precursors for the radiosynthesis of tracers for imaging studies. Key to activating aliphatic substrates is the decreased steric hindrance of the PMe3, allowing for very fast formation of phosphinimine intermediates and subsequent cyclisation to the hydantoin ring in presence of CO2. The rapid nature of the reaction provided high yields with sub-stoichiometric 11C with an activity incorporation sufficient for PET imaging. High isolated yields were obtained for direct synthesis with 13C on a wider substrate scope, which bodes well for labelling of various hydantoins.

Conflicts of interest

There are no conflicts to declare.

Notes and references

  1. (a) B. H. Rotstein, S. H. Liang, M. S. Placzek, J. M. Hooker, A. D. Gee, F. Dolle, A. A. Wilson and N. Vasdev, Chem. Soc. Rev., 2016, 45, 4708–4726 RSC; (b) G. Antoni, J. Labelled Compd. Radiopharm., 2015, 58, 65–72 CrossRef CAS PubMed.
  2. (a) S. R. Ellis, E. Hall, M. Panchal, B. Flinders, J. Madsen, G. Koster, R. M. A. Heeren, H. W. Clark and A. D. Postle, J. Lipid. Res., 2021, 62, 100023 CrossRef CAS PubMed; (b) A. Thomen, N. Najafinobar, F. Penen, E. Kay, P. P. Upadhyay, X. Li, N. T. N. Phan, P. Malmberg, M. Klarqvist, S. Andersson, M. E. Kurczy and A. G. Ewing, ACS Nano, 2020, 14, 4316–4325 CrossRef CAS PubMed; (c) A. R. Buchberger, K. DeLaney, J. Johnson and L. Li, Anal. Chem., 2018, 90, 240–265 CrossRef CAS PubMed.
  3. (a) M. Xu, A. R. Jupp, M. S. E. Ong, K. I. Burton, S. S. Chitnis and D. W. Stephan, Angew. Chem., Int. Ed., 2019, 58, 5707–5711 CrossRef CAS PubMed; (b) M. Xu, A. R. Jupp and D. W. Stephan, Angew. Chem., Int. Ed., 2017, 56, 14277–14281 CrossRef CAS PubMed; (c) F. Shi, Y. Deng, T. SiMa, J. Peng, Y. Gu and B. Qiao, Angew. Chem., Int. Ed., 2003, 42, 3257–3260 CrossRef CAS PubMed; (d) M. J. Fuchter, C. J. Smith, M. W. Tsang, A. Boyer, S. Saubern, J. H. Ryan and A. B. Holmes, Chem. Commun., 2008, 2152–2154 RSC.
  4. J. P. Bow and P. J. Riss, Chem. Methods, 2020, 1, 139–141 CrossRef.
  5. (a) J. M. Hooker, A. T. Reibel, S. M. Hill, M. J. Schueller and J. S. Fowler, Angew. Chem., Int. Ed., 2009, 48, 3482–3485 CrossRef CAS PubMed; (b) P. J. Riss, S. Lu, S. Telu, F. I. Aigbirhio and V. W. Pike, Angew. Chem., Int. Ed., 2012, 51, 2698–2702 CrossRef CAS PubMed; (c) A. Del Vecchio, F. Caille, A. Chevalier, O. Loreau, K. Horkka, C. Halldin, M. Schou, N. Camus, P. Kessler, B. Kuhnast, F. Taran and D. Audisio, Angew. Chem., Int. Ed., 2018, 57, 9744–9748 CrossRef CAS PubMed.
  6. C. Taddei and A. D. Gee, J. Labelled Compd. Radiopharm., 2018, 61, 237–251 CrossRef CAS PubMed.
  7. A. K. Haji Dheere, N. Yusuf and A. Gee, Chem. Commun., 2013, 49, 8193–8195 RSC.
  8. K. Horkka, K. Dahl, J. Bergare, C. S. Elmore, C. Halldin and M. Schou, ChemistrySelect, 2019, 4, 1846–1849 CrossRef CAS.
  9. (a) V. Babin, A. Sallustrau, O. Loreau, F. Caille, A. Goudet, H. Cahuzac, A. Del Vecchio, F. Taran and D. Audisio, Chem. Commun., 2021, 57, 6680–6683 RSC; (b) HBr salts of triphenylphosphinimines with simple aliphatic N-substituents were reported when a previous version of this manuscript was under review, see: U. S. Ismailani, M. Munch, B. A. Mair and B. H. Rotstein, Chem. Commun., 2021, 57, 5266–5269 RSC.
  10. A. V. Mossine, A. F. Brooks, I. M. Jackson, C. A. Quesada, P. Sherman, E. L. Cole, D. J. Donnelly, P. J. Scott and X. Shao, Bioconjugate Chem., 2016, 27, 1382–1389 CrossRef CAS PubMed.
  11. E. W. van Tilburg, A. D. Windhorst, M. van der Mey and J. D. M. Herscheid, J. Labelled Compd. Radiopharm., 2006, 49, 321–330 CrossRef CAS.
  12. M. Köhn and R. Breinbauer, Angew. Chem., Int. Ed., 2004, 43, 3106–3116 CrossRef PubMed.
  13. (a) H. Staudinger and J. Meyer, Helv. Chim. Acta, 1919, 2, 635–646 CrossRef CAS; (b) H. Zimmer, M. Jayawant and P. Gutsch, J Org. Chemi., 1970, 35, 2826–2828 CrossRef CAS; (c) L. Horner and H. Oediger, Liebigs Ann., 1959, 627, 142–162 CrossRef; (d) P. Molina, M. Alajarin and A. Arques, Synthesis, 1982, 596–597 CrossRef CAS.
  14. A. Del Vecchio, A. Talbot, F. Caille, A. Chevalier, A. Sallustrau, O. Loreau, G. Destro, F. Taran and D. Audisio, Chem. Commun., 2020, 56, 11677–11680 RSC.
  15. (a) R. Appel, W. Büchner and E. Guth, Liebigs Ann., 1958, 618, 53–58 CrossRef CAS; (b) R. Appel and A. Hauss, Angew. Chem., 1959, 71, 626 CrossRef CAS.
  16. C. Jiang and D. W. Stephan, Dalton Trans., 2013, 42, 630–637 RSC.
  17. (a) W.-W. du Mont, M. Bätcher, S. Pohl and W. Saak, Angew. Chem., Int. Ed. Engl., 1987, 26, 912–913 CrossRef; (b) F. Ruthe, Chem. Commun., 1997, 1947–1948 RSC; (c) P. Deplano, S. M. Godfrey, F. Lsaia, C. A. McAuliffe, M. L. Mercurp and E. F. Trogu, Chem. Ber., 1997, 130, 299–305 CrossRef CAS.
  18. (a) C. A. Tolman, J. Am. Chem. Soc., 1970, 92, 2956–2965 CrossRef CAS; (b) C. A. Tolman, Chem. Rev., 1977, 77, 313–348 CrossRef CAS.
  19. N. Yamazaki, F. Higashi and T. Iguchi, Tetrahedron Lett., 1974, 15, 1191–1194 CrossRef.

Footnote

Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d2cc01754g

This journal is © The Royal Society of Chemistry 2022
Click here to see how this site uses Cookies. View our privacy policy here.